Slater, Sarah

Systemic Chemotherapy with or without Cetuximab in Patients with Resectable Colorectal Liver Metastasis (New EPOC): Long-Term Results of a Multicentre, Randomised, Controlled, Phase 3 Trial

Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., Stanton, L., Radford, M., Corkhill, A., Griffiths, G. O., et al. (2020) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 255

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., et al. (2024) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 90

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Pinato, D. J., Cortellini, A., Sukumaran, A., Cole, T., Pai, M., Habib, N., Spalding, D., Sodergren, M. H., Martinez, M., Dhillon, T., et al. (2021) · BMC Cancer

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 79

Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma

D'Alessio, A., Pai, M., Spalding, D., Goldin, R. D., Scheiner, B., Korolewicz, J., Fulgenzi, C. A. M., Ward, C., Yip, V., Slater, S., et al. (2023) · Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 17